Lobbying

Apixio's latest lobbying report covers Q1 2025, at $30K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.

Apixio

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Apixio lobbying by quarter
Apixio lobbying by quarter
QuarterAmountReports
Q4 2022$30K1
Q1 2023$30K1
Q2 2023$30K1
Q3 2023$30K1
Q4 2023$30K1
Q1 2024$30K1
Q2 2024$30K1
Q3 2024$30K1
Q4 2024$30K1
Q1 2025$30K1
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$180K · 6 reports
  • Medicare and Medicaid$30K · 1 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES6 reports
  • SENATE6 reports
  • Centers For Medicare and Medicaid Services (CMS)1 reports

Firms it paid

Firm
Hooper, Lundy & Bookman, P.C.$300K10 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
25/04/18for Q1 2025Hooper, Lundy & Bookman, P.C.$30K
25/01/17for Q4 2024Hooper, Lundy & Bookman, P.C.$30K
24/10/17for Q3 2024Hooper, Lundy & Bookman, P.C.$30K
24/07/18for Q2 2024Hooper, Lundy & Bookman, P.C.$30K
24/04/19for Q1 2024Hooper, Lundy & Bookman, P.C.$30K
24/01/18for Q4 2023Hooper, Lundy & Bookman, P.C.$30K
23/10/19for Q3 2023Hooper, Lundy & Bookman, P.C.$30K
23/07/20for Q2 2023Hooper, Lundy & Bookman, P.C.$30K
23/04/20for Q1 2023Hooper, Lundy & Bookman, P.C.$30K
23/01/19for Q4 2022Hooper, Lundy & Bookman, P.C.$30K